Is the therapeutic application of neurotrophic factors dead?

Annals of Neurology

Volumn 51, Issue 1, 2002, Pages 8-11

  Apfel, Stuart C ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b PURDUE PHARMA L P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTROPHIC FACTOR; VIRUS VECTOR;

BLOOD BRAIN BARRIER; EDITORIAL; HERPES SIMPLEX VIRUS; LATENT PERIOD; NONHUMAN; PRIORITY JOURNAL; SENSORY NEUROPATHY; SPINAL GANGLION;

ANIMALS; HUMANS; NERVE GROWTH FACTORS; NERVOUS SYSTEM DISEASES; TREATMENT FAILURE;

EID: 0036135141     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10099     Document Type: Editorial

References (30)

1. The nerve growth factor: 35 Years later
2. A nerve growth stimulating factor isolated from sarcomas 37 and 180
3. Neurotrophic factors in the treatment of neurotoxicity: An overview
4. Nerve growth factor administration protects against experimental diabetic sensory neuropathy
5. Nerve growth factor alleviates a painful peripheral neuropathy in rats
6. The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease
7. Arrest of motor neuron disease in wobbler mice co-treated with CNTF and BDNF
8. Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury
9. Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury
10. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor
11. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
12. A placebo-controlled trial of recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis
13. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis
14. A controlled trial of recombinant methionyl human BDNF in ALS
15. Effect of recombinant human insulin-like growth factor-1 on progression of ALS: A placebo-controlled study
16. A placebo-controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis
17. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy
18. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial
19. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection
20. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease
21. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease
22. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
23. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial)
24. Gene delivery and gene therapy with herpes simplex virus-based vectors
25. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors
26. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
27. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease
28. Intercostal nerve implants transduced with an adenoviral vector encoding neurotrophin-3 promote regrowth of injured rat corticospinal tract fibers and improve hindlimb function
29. In vivo gene therapy for pyridoxine-induced neuropathy by Herpes Simplex Virus-mediated gene transfer of neurotrophin-3